1-8 of 8
Masashi Taki
Close
Sort by
Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami
Journal: Blood
Blood (2023) 142 (Supplement 1): 3991.
https://doi.org/10.1182/blood-2023-173073
Published: 2023
Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami
Journal: Blood
Blood (2022) 140 (Supplement 1): 2742–2744.
https://doi.org/10.1182/blood-2022-157249
Published: 2022
Journal Articles

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Midori Shima, Masashi Taki, Rie Shirayama, Tadashi Matsushita, Yasuharu Nishida, Azusa Nagao, Yoshiyuki Ogawa, Kazuo Kawasugi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11304–11305.
https://doi.org/10.1182/blood-2022-167449
Published: 2022
Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1186.
https://doi.org/10.1182/blood-2018-99-115792
Published: 2018
Journal Articles

Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm™5 Clinical Trial

Susan Kearney, MD, Elena Santagostino, Manuel Carcao, MD, Faraizah Abdul Karim, MD, Masashi Taki, MD PhD, Meng Yao Lu, MD, May-Lill Garly, MD PhD, Marek Zak, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1092.
https://doi.org/10.1182/blood.V130.Suppl_1.1092.1092
Published: 2017
Journal Articles

Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI

Keiji Nogami, MD PhD, Masashi Taki, MD PhD, Tadashi Matsushita, MD PhD, Shouichi Ohga, MD PhD, Hideji Hanabusa, Toshiaki Oka, MD, Yasuo Horikoshi, MD, Kagehiro Amano, MD PhD, Midori Shima, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3526.
https://doi.org/10.1182/blood.V126.23.3526.3526
Published: 2015
Journal Articles

Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study

Midori Shima, MD PhD, Hideji Hanabusa, MD, Masashi Taki, MDPhD, Tadashi Matsushita, MD PhD, Tetsuji Sato, MD, Katsuyuki Fukutake, MD PhD, Naoki Fukazawa, Shingo Maisawa, Koichiro Yoneyama, Keiji Nogami, MD PhD
Journal: Blood
Blood (2014) 124 (21): 691.
https://doi.org/10.1182/blood.V124.21.691.691
Published: 2014
Journal Articles

Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B- Interim Result of Post Marketing Surveillance Study -

Takashi Suzuki, MD, PhD, Katsuyuki Fukutake, MD, PhD, Kagehiro Amano, MD, PhD, Hideji Hanabusa, MD, Masashi Taki, MD, PhD, Tadashi Matsushita, MD, PhD, Midori Shima, MD, PhD, Michio Sakai, MD, PhD, Masahiro Iizuka, Yoshiyuki Shibasaki
Journal: Blood
Blood (2012) 120 (21): 3378.
https://doi.org/10.1182/blood.V120.21.3378.3378
Published: 2012